The innovative drug sector is emerging as a new driver of export growth, fueled largely by cross-border out-licensing, with the NewCo model and direct overseas commercialization also gaining traction, ...
ProKidney Corp. faces weak Phase 2 rilparencel data and a cash runway only to mid-2027 ahead of pivotal 2027 Phase 3 results.
On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic ...
Parabilis Medicines is rated a Buy; it leverages rare, genetically simple tumors to validate its Helicon platform. Read more ...
KNOXVILLE, Tenn.-- (BUSINESS WIRE)--Aug 14, 2026-- ...
STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics ...
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its ...
Seattle biotech InduPro has raised $77 million and dosed its first patient in a Phase 1 trial of an experimental cancer drug, ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset ...
Phase 3 TRIUMPH readouts show dose-dependent mean weight loss up to ~30% at 104 weeks in obesity and ~21% in T2D, with ...
HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune ...
At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Q2 2026 Investor Update Conference Call. [Operator Instructions] I would like to now turn the call over to Chris Stamm, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results